Testosterone levels and cause-specific mortality in the older French men without metabolic syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: Previous studies have reported controversial findings regarding the association of testosterone with mortality in older men. This heterogeneity might be partially explained by comorbidities and the presence of metabolic syndrome, as well as differential associations according to causes of death. METHODS: We used data from a random subsample of the Three-City study, in which hormone levels were measured in 338 men ≥65 years without metabolic syndrome who were followed-up for 12 years. Vital status was determined for all participants from different sources. We used inverse-probability-weighted Cox regression to estimate the hazard ratios (HRs) of cause-specific mortality and 95% confidence intervals (CIs). RESULTS: Over the follow-up period, 130 men died (30 from cardiovascular disease, 45 from cancer, 55 from other causes). The association of testosterone with mortality showed significant heterogeneity across causes of death (p=0.027 and p=0.022 for total and bioavailable testosterone, respectively). Higher testosterone levels were associated with increased cardiovascular mortality (HR for 1-standard deviation increase, 1.86; 95% CI, 1.28 to 2.71 and 1.50; 95% CI, 1.04 to 2.17 for total and bioavailable testosterone, respectively). By contrast, there were no significant associations of testosterone with mortality from cancer and other causes. CONCLUSIONS: Our data suggest that the association of testosterone with mortality in men without metabolic syndrome might be differential according to the cause of death. These findings may partially explain the heterogeneity across studies on the relationship between testosterone levels and mortality.
Abstract
OBJECTIVES: Previous studies have reported controversial findings regarding the association of testosterone with mortality in older men. This heterogeneity might be partially explained by comorbidities and the presence of metabolic syndrome, as well as differential associations according to causes of death. METHODS: We used data from a random subsample of the Three-City study, in which hormone levels were measured in 338 men ≥65 years without metabolic syndrome who were followed-up for 12 years. Vital status was determined for all participants from different sources. We used inverse-probability-weighted Cox regression to estimate the hazard ratios (HRs) of cause-specific mortality and 95% confidence intervals (CIs). RESULTS: Over the follow-up period, 130 men died (30 from cardiovascular disease, 45 from cancer, 55 from other causes). The association of testosterone with mortality showed significant heterogeneity across causes of death (p=0.027 and p=0.022 for total and bioavailable testosterone, respectively). Higher testosterone levels were associated with increased cardiovascular mortality (HR for 1-standard deviation increase, 1.86; 95% CI, 1.28 to 2.71 and 1.50; 95% CI, 1.04 to 2.17 for total and bioavailable testosterone, respectively). By contrast, there were no significant associations of testosterone with mortality from cancer and other causes. CONCLUSIONS: Our data suggest that the association of testosterone with mortality in men without metabolic syndrome might be differential according to the cause of death. These findings may partially explain the heterogeneity across studies on the relationship between testosterone levels and mortality.
참고문헌 (24)
- Araujo AB, "Clinical review : endogenous testosterone and mortality in men : a systematic review and meta-analysis", J Clin Endocrinol Metab, 96, pp.3007~3019 (2011)
- Laouali N, "Testosterone and all-cause mortality in older men : the role of metabolic syndrome", J Endocr Soc, 2, pp.322~335 (2018)
- Shores MM, "Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study", J Clin Endocrinol Metab, 99, pp.2061~2068 (2014)
- Soisson V, "A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men : the French 3C cohort study", Maturitas, 75, pp.282~288 (2013)
- Khaw KT, "Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men : European prospective investigation into cancer in Norfolk(EPIC-Norfolk)Prospective Population Study", Circulation, 116, pp.2694~2701 (2007)
- 3C Study Group, "Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population", Neuroepidemiology, 22, pp.316~325 (2003)
- Laouali N, "Oestradiol level, oestrogen receptors, and mortality in elderly men: the three-city cohort study", Clin Endocrinol(Oxf), 89, pp.514~525 (2018)
- Alberti KG, "The metabolic syndrome--a new worldwide definition", Lancet, 366, pp.1059~1062 (2005)
- Lau B, "Competing risk regression models for epidemiologic data", Am J Epidemiol, 170, pp.244~256 (2009)
- Lau B, "Competing risk regression models for epidemiologic data", Am J Epidemiol, 170, pp.244~256 (2009)
- Hyde Z, "Low free testosterone predicts mortality from cardiovascular disease but not other causes : the Health in Men Study", J Clin Endocrinol Metab, 97, pp.179~189 (2012)
- Yeap BB, "Lower testosterone levels predict incident stroke and transient ischemic attack in older men", J Clin Endocrinol Metab, 94, pp.2353~2359 (2009)
- Maggio M, "Welcoming low testosterone as a cardiovascular risk factor", Int J Impot Res, 21, pp.261~264 (2009)
- Srinath R, "Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study", J Clin Endocrinol Metab, 100, pp.1602~1608 (2015)
- Vikan T, "Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men : the Tromsø Study", Eur J Endocrinol, 161, pp.435~442 (2009)
- Araujo AB, "Sex steroids and all-cause and cause-specific mortality in men", Arch Intern Med, 167, pp.1252~1260 (2007)
- Sueoka KT, "Higher endogenous testosterone levels associated with increased risk of coronary heart disease in elderly men : a prospective study", Endocr Rev, 31, pp.S858~ (2010)
- Xu L, "Testosterone therapy and cardiovascular events among men : a systematic review and meta-analysis of placebo-controlled randomized trials", BMC Med, 11, pp.108~ (2013)
- Bhasin S, "Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle", J Clin Endocrinol Metab, 90, pp.678~688 (2005)
- Far HR, "Cardiac hypertrophy in deceased users of anabolic androgenic steroids : an investigation of autopsy findings", Cardiovasc Pathol, 21, pp.312~316 (2012)
- Laughlin GA, "Low serum testosterone and mortality in older men", J Clin Endocrinol Metab, 93, pp.68~75 (2008)
- Holmboe SA, "The association of reproductive hormone levels and all-cause, cancer, and cardiovascular disease mortality in men", J Clin Endocrinol Metab, 100, pp.4472~4480 (2015)
- Haring R, "Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79", Eur Heart J, 31, pp.1494~1501 (2010)
- Hsu B, "Temporal changes in androgens and estrogens are associated with all-cause and cause-specific mortality in older men", J Clin Endocrinol Metab, 101, pp.2201~2210 (2016)